Please try another search
For the three months ended 31 March 2022, LOTTE NON-LIFE INSURANCE CO., LTD. revenues decreased 4% to W810.61B. Net income applicable to common stockholders decreased 65% to W22B. Revenues reflect Loss on Valt of FA as Measured at FVTPL decrease of 70% to -W67.8B, Premium income decrease of 2% to W558.63B, Gain on Valt of FA as Measured at FVTPL decrease of 8% to W19.27B.
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Revenue | 650348.29 | 511789.33 | 571048.57 | |
Operating Income | 98348.93 | 205383.11 | 388752.66 | 163549.38 |
Net Income | 38757.45 | 181554.86 | 24911.34 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Assets | 14861427.32 | 14842983.22 | 13677961.13 | 13721152.96 |
Total Liabilities | 13767797.33 | 13586751.53 | 12331294 | 12522436.77 |
Total Equity | 1093629.99 | 1256231.69 | 1346667.13 | 1198716.19 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -108391.31 | 749610.63 | 349475.69 | 417138.31 |
Cash From Investing Activities | -411067.45 | 55015.7 | -392617.74 | 95049.68 |
Cash From Financing Activities | -24556.13 | 65085.49 | -34535.75 | -823259.84 |
Net Change in Cash | -542745.93 | 869090.31 | -76820.68 | -310768.5 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review